Drugs for Immunotherapy Market Report 2026

Drugs for Immunotherapy Market Overview

• Drugs for Immunotherapy market size has reached to $310.48 billion in 2025 • Expected to grow to $570 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Increasing Healthcare Expenditure In Drugs For Immunotherapy Market • Market Trend: Innovation In Drugs For Immunotherapy Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Drugs for Immunotherapy Market?

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others.

What Is The Drugs for Immunotherapy Market Growth Forecast?

The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $570 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of bispecific and conjugated antibodies, expansion of personalized immunotherapy, increasing adoption of checkpoint inhibitors, rising investments in therapeutic vaccine research, integration of digital patient monitoring and AI-guided immunotherapy. Major trends in the forecast period include rising adoption of monoclonal antibodies and checkpoint inhibitors, growth in cancer immunotherapy and autoimmune disease treatments, increasing development of therapeutic and preventive vaccines, expansion of t-cell receptor and cytokine-based therapies, integration of immunotherapy in ambulatory and hospital-based care.

Global Drugs for Immunotherapy Market Segmentation

1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies 2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma 3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12) 4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines 5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors 6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy

What Is The Driver Of The Drugs for Immunotherapy Market?

The increasing healthcare expenditure is anticipated to propel the growth of the drugs for immunotherapy market going forward. Healthcare expenditure refers to the entire amount of money spent on healthcare goods and services within a certain region or country over a specified period, which includes spending on doctor visits, hospital stays, surgeries, diagnostic procedures, and treatments. Health care expenditure, such as financial resources, is allocated by individuals, healthcare providers, insurance companies, and government agencies to cover the costs associated with drugs for immunotherapy and treatments. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the increasing healthcare expenditure is driving the growth of the drugs for immunotherapy industry.

Key Players In The Global Drugs for Immunotherapy Market

Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

Global Drugs for Immunotherapy Market Trends and Insights

Major companies operating in the drugs for immunotherapy market are focusing on innovating new products, such as Keytruda (pembrolizumab), to provide reliable services to customers. Keytruda (pembrolizumab) is a type of immunotherapy with a targeted therapy drug called an immune checkpoint inhibitor for adult patients. For Instance, In January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab), which was approved by the Food and Drug Administration, a US-based federal agency. Keytruda (pembrolizumab) immunotherapy is used to treat various types of cancer by working with the immune system to help fight cancer cells. KEYTRUDA (pembrolizumab) is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This is a significant development in the field of cancer treatment, and it is expected to have a positive impact on the healthcare industry.

What Are Latest Mergers And Acquisitions In The Drugs for Immunotherapy Market?

In December 2024, Pfizer Inc., a US-based pharmaceutical industry company, acquired Seagen for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio by expanding into advanced immunotherapy treatments using Seagen’s innovative antibody-drug conjugates (ADCs) for targeted cancer therapy. Seagen Inc. is a US-based biotechnology company that specializes in manufacturing antibody-drug conjugates (ADCs).

Regional Insights

North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Drugs for Immunotherapy Market?

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drugs for Immunotherapy Market Report 2026?

The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.